News & Updates
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Pancreatic Cancer Vaccine Shows Early Promise i...
UCLA’s Dr. Zev Wainberg discusses results from the AMPLIFY-201 trial and hopes for next-generation vaccines. Researchers are exploring new ways to fight pancreatic cancer, one of the toughest cancers to...
Pancreatic Cancer Vaccine Shows Early Promise i...
UCLA’s Dr. Zev Wainberg discusses results from the AMPLIFY-201 trial and hopes for next-generation vaccines. Researchers are exploring new ways to fight pancreatic cancer, one of the toughest cancers to...
Pancreatic Cancer Vaccine Trial Moves Forward A...
Independent committee recommends ELI-002 7P Phase 2 study continue without changes. Elicio Therapeutics has announced encouraging news for its pancreatic cancer vaccine, ELI-002 7P. An independent committee (IDMC) reviewed early...
Pancreatic Cancer Vaccine Trial Moves Forward A...
Independent committee recommends ELI-002 7P Phase 2 study continue without changes. Elicio Therapeutics has announced encouraging news for its pancreatic cancer vaccine, ELI-002 7P. An independent committee (IDMC) reviewed early...
Off-the-Shelf Cancer Vaccine Shows Strong Resul...
UCLA-led study reports durable immune responses and reduced relapse in patients with KRAS-driven cancers. A groundbreaking study led by UCLA Health researchers has shown promising results for an experimental off-the-shelf...
Off-the-Shelf Cancer Vaccine Shows Strong Resul...
UCLA-led study reports durable immune responses and reduced relapse in patients with KRAS-driven cancers. A groundbreaking study led by UCLA Health researchers has shown promising results for an experimental off-the-shelf...